Previous 10 | Next 10 |
EMERYVILLE, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today it has entered an agreement to acquire Kinnate Biopharma Inc. (NASDAQ: KNTE) for (i) a base cash price of $2.3352 per share (the Base Price) and (ii) an additional cash amount of not more than $0...
SAN FRANCISCO and SAN DIEGO, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc . (Nasdaq: KNTE) (“Kinnate” or the “Company”), a clinical-stage precision oncology company, today announced it has entered into a definitive merger agreement (the "Merger Agreement...
2023-12-12 01:26:03 ET Summary Kinnate Biopharma is focusing on the development of a novel RAF inhibitor to overcome challenges in targeted therapy for melanoma and other BRAF-mutated cancers. The company is narrowing its near-term development to work on the RAF inhibitor exarafen...
2023-11-15 13:30:05 ET Kinnate Biopharma ( KNTE ) +47% . SciSparc ( SPRC ) +46% . Ebix ( EBIX ) +41% . Beauty Health Company ( SKIN ) +35% . Mira Pharmaceuticals ( MIRA ) +38% . Solid Biosciences ( SLDB ) +28% ...
2023-11-15 12:32:14 ET DENVER, Colo., Nov. 15, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Cormedix Inc (NASDAQ: CRMD), SciSparc Ltd (NASDAQ: SPRC), Solid Biosciences Inc (NASDAQ: SLDB), Heron ...
Kinnate Biopharma Inc. (NASDAQ: KNTE) is one today's most active stocks by volume. So far today, approximately 75,328 shares of Kinnate Biopharma Inc. have been exchanged, as compared to an average 30-day volume of 115.51k shares. Kinnate Biopharma Inc., a biopharmaceutical company, focuses on...
2023-11-15 09:50:09 ET DENVER, Colo., Nov. 15, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; SciSparc Ltd (NASDAQ: SPRC), Chemomab Therapeutics Ltd (NASDAQ: CMMB), Cellectis SA (NASDAQ: CLLS), AstraZene...
2023-11-15 08:45:04 ET SciSparc ( SPRC ) +86% Positive Results Show its Treatment has a Remarkable Impact on Alzheimer's Agitation. Kinnate Biopharma ( KNTE ) +41% . Solid Biosciences ( SLDB ) +27% gets FDA okay for clinical testing of DMD gene th...
2023-11-09 17:48:39 ET Kinnate Biopharma press release ( NASDAQ: KNTE ): Q3 GAAP EPS of -$0.65 beats by $0.04 . As of September 30, 2023, total cash, cash equivalents and investments were $180.3 million, which is expected to fund current operations into at least the se...
Reported promising exarafenib combination data in NRAS mutant melanoma; intend to select two doses in the fourth quarter of 2023 for further development Plan to file KIN-8741 c-MET inhibitor Investigational New Drug application and nominate a drug candidate for brain-penetrant CDK4 select...
News, Short Squeeze, Breakout and More Instantly...
Kinnate Biopharma Inc. Company Name:
KNTE Stock Symbol:
NASDAQ Market:
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
EMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA) ("XOMA" or the "Company"), a biotechnology royalty aggrega...
EMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) (“XOMA” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced th...